The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer.
Angela DeMichele
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Amy Sanders Clark
No relevant relationships to disclose
Daniel Heitjan
No relevant relationships to disclose
Sophia Randolph
Employment or Leadership Position - Pfizer
Maryann Gallagher
No relevant relationships to disclose
Priti Lal
No relevant relationships to disclose
Michael D Feldman
No relevant relationships to disclose
Paul J. Zhang
No relevant relationships to disclose
Allison Schnader
No relevant relationships to disclose
Kelly Zafman
No relevant relationships to disclose
Susan M. Domchek
No relevant relationships to disclose
Keerthi Gogineni
No relevant relationships to disclose
Stephen Michael Keefe
Research Funding - Pfizer
Kevin R. Fox
Consultant or Advisory Role - Genomic Health; Novartis
Peter J. O'Dwyer
Research Funding - Pfizer